- Home
- BUD vs NVO Comparison
BUD vs NVO Comparison
Compare BUD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUD | NVO |
|---|---|---|
| Founded | 1366 | 1923 |
| Country | Belgium | Denmark |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.0B | 203.2B |
| IPO Year | 2016 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BUD | NVO |
|---|---|---|
| Price | $78.76 | $48.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 11 |
| Target Price | ★ $92.00 | $51.00 |
| AVG Volume (30 Days) | 1.9M | ★ 12.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | 1.33% | ★ 3.19% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.01 | N/A |
| Revenue Next Year | $3.67 | $3.70 |
| P/E Ratio | $23.27 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.79 | $35.12 |
| 52 Week High | $86.60 | $64.16 |
Technical Indicators
Market Signals| Indicator | BUD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 54.56 |
| Support Level | $78.02 | $47.93 |
| Resistance Level | $82.01 | $50.45 |
| Average True Range (ATR) | 1.05 | 0.95 |
| MACD | -0.33 | 0.13 |
| Stochastic Oscillator | 18.22 | 94.29 |
Price Performance
Historical ComparisonAbout BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the top five consumer product companies by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 acquired SABMiller.
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.